Page 301 - Read Online

Harrod et al. Hepatoma Res 2019;5:28 I http://dx.doi.org/10.20517/2394-5079.2019.15 Page 13 of 13

65. Ji F, Li Z. Letter : the antiviral activity of sorafenib in patients with hepatitis C-related hepatocellular carcinoma. Aliment Pharmacol
Ther 2013;37:372-3.
66. Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, et al. Prognostic factors and predictors of sorafenib benefit in patients
with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol 2017;67:999-1008.
67. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol
2018;15:599-616.
68. Liverpool, U. of. HEP Drug Interaction checker.
69. Revuelta-Herrero JL, Giménez-Manzorro A, Matilla-Peña A, Herranz-Alonso A, Sanjurjo-Sáez M. Concomitant use of sorafenib with
ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice. J Clin Pharm Ther 2018;43:906-9.
70. Moreno-Cubero E, Larrubia JR. Specific CD8+ T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
World J Gastroenterol 2016;22:6469-83.
71. Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, et al. A randomized, double-blind, placebo-controlled assessment of bms-
936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis c virus infection. PLoS
One 2013;8:1-11.
72. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
73. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma
previously treated with sorafenib ( KEYNOTE-224 ): a non-randomised , open-label phase 2 trial. Lancet Oncol 2018;940-52.
74. Mazouz S, Boisvert M, Shoukry NH, Lamarre D. Reversing immune dysfunction and liver damage after direct-acting antiviral
treatment for hepatitis C. Can Liver J 2018;1:78-105.
75. Meissner EG, Kohli A, Higgins J, Lee YJ, Prokunina O, et al. Rapid changes in peripheral lymphocyte concentrations during
interferon-free treatment of chronic hepatitis c virus infection. Hepatol Commun 2017;1:586-94.
76. AASLD & IDSA. AASLD/IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Clin Liver Dis
(Hoboken) 2018;12:117.
77. Kawaoka T, Aikata H, Teraoka Y, Inagaki Y, Honda F, et al. Impact of hepatitis c virus eradication on the clinical outcome of patients
with hepatitis c virus-related advanced hepatocellular carcinoma treated with sorafenib. Oncology 2017;92:335-46.
78. Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, et al. Sofosbuvir and ribavirin prevent recurrence of hcv infection after liver
transplantation: an open-label study. Gastroenterology 2015;148:100-7.
79. Chang CY, Nguyen P, Le A, Zhao C, Ahmed A, et al. Real-world experience with interferon-free, direct acting antiviral therapies in
Asian Americans with chronic hepatitis C and advanced liver disease. Medicine (Baltimore) 2017;96:e6128.